上海凯利泰医疗科技股份有限公司 第五届董事会独立董事 2023 年第一次专门会议审核意见 （本页无正文，为《上海凯利泰医疗科技股份有限公司第五届董事会独立董事 2023 年第一次专门会议审核意见》之签字页） 独立董事签字： 郑卫茂 鲁旭波 根据《公司法》《证券法》《上市公司独立董事管理办法》《深圳证券交易所 创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作（2023 年修订）》等法律法规、规范性文件及《上海凯利泰 医疗科技股份有限公司独立董事工作制度》的有关规定，公司于 2023 年 12 月 6 日以邮件的方式发出召开 2023 年第一次独立董事专门会议的通知，并于 2023 年 12 月 12 日以通讯的方式召开。 本次会议应出席独立董事 3 人，实际出席独立董事 3 人，独立董事郑卫茂、 鲁旭波、戴雪光亲自出席了会议。与会独立董事共同推举郑卫茂为独立董事专门 会议的召集人和主持人。 会议召开程序符合有关法律、行政法规、部门规章、规范性文件和《公司章 程》的规定。 全体独立董事本着认真、负责的态度，对公司第五届董事会第十二次会议审 议的相关事项发表审核意见如下 ...

证券代码：300326 证券简称：凯利泰 公告编号：2023-047 上海凯利泰医疗科技股份有限公司 第五届监事会第十二次会议决议公告 3、本次监事会会议应出席的监事 3 名，实际出席会议的监事 3 名（其中： 周志强以通讯表决方式出席会议）。 4、会议由周志强先生主持，公司董事会秘书列席本次会议。 5、本次会议的召集、召开符合《中华人民共和国公司法》和《上海凯利泰 医疗科技股份有限公司章程》的规定。 二、监事会会议审议情况 1、审议通过了《关于与关联方共同投资暨关联交易的议案》 为满足公司未来战略发展需求，公司拟投资上海赛立维生物科技有限公司 （以下简称"上海赛立维"）。本次公司拟以自有资金人民币 5,000,000 元对上海 赛立维进行增资，认缴上海赛立维注册资本人民币 56,309 元。 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、上海凯利泰医疗科技股份有限公司（以下简称"公司"）于 2023 年 12 月 11日以邮件方式向公司各监事发出关于召开第五届监事会第十二次会议的通知。 2、公司于 2023 年 12 月 13 ...

证券代码：300326 证券简称：凯利泰 公告编号：2023-046 关联董事袁征、王正民回避表决。表决结果：本议案以 5 票同意、0 票反对、 0 票弃权、2 票回避获得通过。 第五届董事会独立董事事前召开了 2023 年第一次专门会议，就本议案出具 了同意的审核意见，并同意提交公司第五届董事会第十二次会议审议，具体内容 请详见中国证监会指定信息披露网站公告的《上海凯利泰医疗科技股份有限公司 第五届董事会独立董事 2023 年第一次专门会议审核意见》。 1 上海凯利泰医疗科技股份有限公司 第五届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 上海凯利泰医疗科技股份有限公司（以下简称"公司"）于 2023 年 12 月 6 日以邮件方式向公司各董事发出关于召开第五届董事会第十二次会议的通知，并 于 2023 年 12 月 13 日 16 时在公司会议室以现场结合通讯方式召开。本次董事 会会议应出席的董事 7 名，实际出席会议的董事 7 名，其中袁征、王正民、王冲、 鲁旭波、戴雪光以通讯表决方式出席会议。会议由 ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥213,839,891.49, a decrease of 34.44% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2023 was ¥14,454,178.67, down 77.48% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥11,841,627.63, a decline of 77.01% compared to the previous year[5]. - The basic and diluted earnings per share for Q3 2023 were both ¥0.0194, representing a decrease of 78.25% year-on-year[5]. - Total operating revenue for Q3 2023 was ¥736,542,512.98, a decrease of 20.6% compared to ¥928,386,863.29 in Q3 2022[27]. - Net profit for Q3 2023 was ¥142,929,992.00, a decline of 28.0% from ¥198,371,348.69 in Q3 2022[28]. - Total comprehensive income for Q3 2023 was CNY 166,128,200.70, a decrease from CNY 273,318,125.89 in Q3 2022, representing a decline of approximately 39.2%[29]. Assets and Liabilities - The total assets at the end of Q3 2023 were ¥3,352,417,951.92, a decrease of 1.75% from the end of the previous year[5]. - The company's total assets decreased to ¥3,352,417,951.92 from ¥3,412,148,611.26, a reduction of 1.7%[25]. - Total liabilities decreased significantly to ¥376,937,840.54 from ¥597,447,117.66, a drop of 37.0%[25]. - The company's total liabilities decreased significantly, with current liabilities due within one year dropping by 86.45% to ¥1,571.71 million[11]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥168,267,223.29, down 31.24% compared to the previous year[5]. - The net cash flow from operating activities for the first nine months of 2023 was 16,826.73 million yuan, a decrease of 7,643.31 million yuan or 31.24% compared to the same period in 2022[18]. - Cash inflow from operating activities totaled CNY 946,274,053.34, compared to CNY 1,093,243,683.99 in the same period last year, reflecting a decline of approximately 13.5%[30]. - Cash outflow from operating activities was CNY 778,006,830.05, down from CNY 848,543,289.05, showing a decrease of about 8.3%[30]. - The company's total cash outflow from operating activities decreased by 7,053.65 million yuan, a reduction of 8.31% compared to the previous year[17]. - Net cash flow from operating activities for the period was CNY 168,267,223.29, down from CNY 244,700,394.94 in the previous year, indicating a decrease of about 31.2%[31]. Investment Income - The company's investment income for the year-to-date was ¥2,722.37 million, an increase of 299.52% compared to the same period last year[13]. - The company reported a significant increase in investment income due to the equity investment in Ligetai and Yixin Medical during the reporting period[17]. - The company reported an investment income of ¥27,223,676.10, a significant recovery from a loss of ¥13,644,946.91 in the previous year[28]. - Cash inflow from investment activities was CNY 569,664,054.57, significantly higher than CNY 142,398,840.97 in the previous year, marking an increase of about 299.5%[31]. Expenses - The company experienced a 33.40% reduction in sales expenses, totaling ¥14,176.46 million for the year-to-date[13]. - The company experienced a decrease in sales expenses due to a decline in overall sales scale influenced by centralized procurement policies[17]. - Research and development expenses for Q3 2023 were ¥39,467,061.79, down from ¥45,539,908.36 in Q3 2022, indicating a decrease of 13.9%[27]. Other Comprehensive Income - The company reported a significant increase in other comprehensive income, which rose by 116.85% to ¥4,305.18 million[11]. - Other comprehensive income after tax for Q3 2023 was ¥23,198,208.70, compared to ¥74,946,777.20 in Q3 2022, reflecting a decrease of 69.0%[28].

上海凯利泰医疗科技股份有限公司 2023 年半年度报告全文 上海凯利泰医疗科技股份有限公司 二〇二三年半年度报告 K 凯 利 泰 股票代码: 300326 股票简称:凯利泰 披露日期: 二〇二三年八月二十五日 1 上海凯利泰医疗科技股份有限公司 2023 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人袁征、主管会计工作负责人李元平及会计机构负责人(会计主 管人员)李元平声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本半年度报告涉及的未来计划、发展战略等前瞻性描述不构成公司对投资 者的实质承诺，敬请投资者注意投资风险。公司在本报告第三节 十、公司面临 的风险和应对措施，详细描述了公司经营中可能存在的风险及应对措施，敬请 投资者关注相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 上海凯利泰医疗科技股份有限公司 2023 年半年度报告全文 | | | | 第一节 重要提示 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥294.40 million, a decrease of 7.29% compared to ¥317.55 million in the same period last year[8]. - The net profit attributable to shareholders was ¥74.90 million, down 0.78% from ¥75.49 million year-on-year[8]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥46.51 million, a significant decline of 36.25% from ¥72.96 million in the previous year[8]. - Total operating revenue for Q1 2023 was CNY 294,401,832.83, a decrease of 7.27% compared to CNY 317,546,846.50 in Q1 2022[33]. - Net profit for Q1 2023 was CNY 75,078,222.16, a decline of 1.76% from CNY 76,423,135.11 in Q1 2022[34]. - Total comprehensive income for Q1 2023 was CNY 65,202,506.86, a decrease from CNY 73,320,376.69 in Q1 2022, representing a decline of approximately 8.3%[35]. Cash Flow - The net cash flow from operating activities increased by 23.34% to ¥76.51 million, compared to ¥62.04 million in the same period last year[8]. - Net cash flow from operating activities was CNY 76,514,802.08, an increase of 23.4% compared to CNY 62,035,512.25 in the same period last year[38]. - Total cash inflow from operating activities was 357.18 million, a slight increase of 0.35% from 355.94 million[23]. - Total cash outflow from operating activities decreased by 4.51% to 280.66 million, down from 293.91 million[23]. - Total cash outflow from operating activities was CNY 280,662,503.31, down from CNY 293,905,340.25 in the previous year, indicating improved cash management[38]. - Cash inflow from financing activities increased by 36.84% to 26.51 million, compared to 19.38 million last year[24]. - Cash inflow from financing activities was CNY 26,514,161.43, compared to CNY 19,376,473.22 in the same period last year, reflecting increased financing efforts[38]. - Cash outflow from financing activities surged by 76.24% to 77.69 million, up from 44.08 million[24]. - The company incurred a total of CNY 185,000,000.00 in cash outflow related to investment activities, consistent with the previous year's CNY 185,790,000.00[38]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3.40 billion, a slight decrease of 0.32% from ¥3.41 billion at the end of the previous year[8]. - Total assets as of Q1 2023 amounted to CNY 3,401,111,783.56, slightly down from CNY 3,412,148,611.26 at the end of the previous quarter[31]. - Total liabilities decreased to CNY 524,828,835.39 from CNY 597,447,117.66 in the previous year, reflecting a reduction of 12.14%[31]. - The equity attributable to shareholders of the parent company increased to CNY 2,800,973,334.40 from CNY 2,739,569,604.96, representing a growth of 2.24%[31]. Investment Income - The company reported an investment income of ¥30.02 million from equity swaps, contributing positively to the financial results[11]. - Investment income recognized was 30.02 million due to the fair value difference from the equity swap of Ligetai and Yiting Medical[23]. - The company reported an investment income of CNY 29,188,157.40, a significant recovery from a loss of CNY 2,005,772.10 in the previous year[34]. Other Income and Expenses - The company's other income increased by 336.62% to ¥297.99 million, indicating improved performance in this area[21]. - The orthopedic consumables manufacturing business faced significant adverse impacts due to the implementation of centralized procurement policies, leading to a decline in sales revenue and gross margin[11]. - The company experienced a 50.91% reduction in employee compensation liabilities, reflecting payments made for previously accrued salaries and bonuses[14]. - The company's financial expenses decreased significantly by 109.39% to -¥22.97 million, attributed to reduced interest expenses and increased interest income[21]. - Research and development expenses decreased to CNY 13,021,152.19, down 18.19% from CNY 15,916,371.28 in the same period last year[34]. - Other comprehensive income after tax for Q1 2023 was CNY -9,875,715.30, compared to CNY -3,102,758.42 in Q1 2022, indicating a worsening in this area[34]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 54,605[26]. - The largest shareholder, Yongjin Investment Holdings, holds 6.99% of shares, totaling 50.1 million shares[26]. Cash and Cash Equivalents - The company's cash and cash equivalents decreased to 659.64 million from 707.49 million at the beginning of the year[29]. - Cash and cash equivalents at the end of the period stood at CNY 654,769,877.61, up from CNY 620,967,187.64 at the end of Q1 2022[38]. - The company's cash and cash equivalents were not explicitly stated but are part of the total current assets of CNY 1,801,550,584.30[31]. Audit Status - The report was not audited, indicating that the figures are preliminary and subject to change[39].

Financial Performance - Revenue for 2022 was RMB 1,166.04 million, a decrease of 8.08% year-over-year[6] - Net profit attributable to shareholders was a loss of RMB -21.28 million, a decrease of 113.16% year-over-year[6] - Revenue in 2022 decreased by 8.08% to 1,166,042,082.06 yuan compared to 1,268,579,510.95 yuan in 2021[26] - Net profit attributable to shareholders in 2022 was -21,282,494.18 yuan, a decrease of 113.16% compared to 161,775,976.76 yuan in 2021[26] - Net cash flow from operating activities in 2022 was 236,756,963.51 yuan, a decrease of 37.39% compared to 378,155,561.13 yuan in 2021[26] - Basic earnings per share in 2022 was -0.0296 yuan, a decrease of 113.21% compared to 0.2241 yuan in 2021[26] - Total assets at the end of 2022 were 3,412,148,611.26 yuan, a decrease of 2.78% compared to 3,509,647,722.46 yuan at the end of 2021[26] - Revenue in Q4 2022 was 237,655,218.77 yuan, the lowest among the four quarters[29] - Net profit attributable to shareholders in Q4 2022 was -218,097,422.86 yuan, the only quarter with a negative profit[29] - Revenue for the reporting period was RMB 11,660.421 million, a decrease of 8.08% year-on-year[94] - Net profit attributable to shareholders of the listed company was RMB -212.825 million, a decrease of 113.16% year-on-year[94] - Vertebroplasty minimally invasive business achieved sales revenue of RMB 539.3335 million, a decrease of 2.22% year-on-year[96] - Low-temperature radiofrequency business achieved sales revenue of RMB 205.4081 million, an increase of 25.05% year-on-year[96] - Trauma and spine orthopedic implant business achieved sales revenue of RMB 106.1527 million, a decrease of 31.08% year-on-year[97] - Medical device trade business achieved sales revenue of RMB 140.3668 million, a decrease of 27.98% year-on-year[97] - Disinfection and sterilization service revenue decreased by 19.58% to 155.01 million yuan in 2022, compared to 192.75 million yuan in 2021[98] - The fair value of the investment in Kahtnu Surgical Inc. was written down to zero, resulting in a fair value change loss of 18.25 million yuan, compared to a gain of 28.15 million yuan in 2021[98] - Net cash flow from operating activities decreased by 37.39% to 236.76 million yuan in 2022, primarily due to reduced sales revenue and government subsidies[99] - R&D investment decreased by 7.54% to 68.65 million yuan in 2022, accounting for 5.89% of operating revenue, an increase of 0.04 percentage points compared to the previous year[102] - Total operating revenue decreased by 8.08% to 1.17 billion yuan in 2022, with domestic market revenue decreasing by 11.89% to 998.30 million yuan[109] - Revenue from radiofrequency ablation products increased by 25.05% to 205.41 million yuan in 2022[109] - Revenue from orthopedic spine and trauma products decreased by 31.08% to 106.15 million yuan in 2022[109] - Revenue from the international market increased by 23.77% to 167.74 million yuan in 2022[109] - Revenue from other businesses increased by 78.78% to 19.77 million yuan in 2022[109] - Medical device manufacturing revenue decreased by 2.18% to 850,894,350.98 yuan, with a gross margin of 76.88%[110] - Medical device trade revenue dropped by 27.98% to 140,366,820.31 yuan, with a gross margin of 14.73%[110] - Domestic market revenue declined by 11.89% to 998,297,178.14 yuan, while the foreign market revenue increased by 23.77% to 167,744,903.91 yuan[110] - Sales volume of medical device manufacturing decreased by 44.00% to 2,965,281 units, and production volume dropped by 55.63% to 2,863,751 units[111] - Medical device trade sales volume surged by 1,708.54% to 3,722,399 units, and production volume increased by 1,112.21% to 4,102,017 units[111] - Material costs for medical device manufacturing increased by 5.52% to 108,723,283.21 yuan, accounting for 25.72% of total operating costs[113] - Depreciation and amortization costs for medical device manufacturing rose by 13.98% to 12,136,318.60 yuan[113] - Sales expenses decreased by 1.30% year-over-year, amounting to 283,916,369.87 RMB[120] - Management expenses increased by 25.51% year-over-year, reaching 154,375,192.25 RMB[120] - Financial expenses decreased by 55.14% year-over-year, totaling 4,058,568.53 RMB[121] - R&D expenses decreased by 12.00% year-over-year, amounting to 61,401,962.45 RMB[121] - Income tax expenses decreased by 47.50% year-over-year, totaling 21,689,257.32 RMB[121] - The net cash flow from operating activities in 2022 was RMB 236,756,963.51, a decrease of 37.39% compared to 2021, mainly due to reduced sales revenue and government subsidies[126][127] - The net cash flow from investment activities in 2022 was RMB -163,776,092.95, a decrease of 49.96% compared to 2021, primarily due to reduced cash inflows from investment recoveries and disposals[127] - The net cash flow from financing activities in 2022 was RMB -104,092,116.51, an increase of 56.44% compared to 2021, mainly due to reduced bank loan repayments and interest payments[128] - Operating cash flow for the reporting period was RMB 236.757 million, while net profit was RMB -23.9528 million, with a significant difference due to a goodwill impairment provision of RMB 197.9948 million for Aidier and a fair value loss of RMB 18.0198 million for Kahtnu Surgical Inc[129] - Investment income was RMB -10.6531907 million, a 470.64% change, mainly due to equity method investment losses of RMB 16.9288 million and disposal of subsidiaries[131] - Fair value change loss was RMB -18.24878 million, a 806.21% change, as the investment in Kahtnu Surgical Inc was written down to zero due to operational difficulties[132] - Asset impairment loss was RMB -201.05935488 million, a 8,882.55% change, including goodwill impairment of RMB 197.9948 million and fixed asset impairment of RMB 1.7416 million[132] - Accounts receivable decreased by 19.04% to RMB 367.50530952 million, mainly due to reduced receivables and bad debt provisions[134] - Inventory increased by 18.13% to RMB 346.83154410 million, influenced by external environment and centralized procurement policies[134] - Short-term loans decreased by 6.35% to RMB 170.00646496 million, as the company repaid bank loans[134] - Long-term loans decreased by RMB 100 million, reclassified to current liabilities due to maturity within one year[134] - Trading financial assets increased by 48.71% to RMB 264.4 million, mainly due to an increase in undeposited bank wealth management products[134] - Notes receivable increased to RMB 9.15221257 million, representing undeposited bank acceptance bills[134] - Prepaid accounts increased by 46.61% compared to the beginning of the period, mainly due to increased prepayments by subsidiaries Runzhi Tai and Jienuo Medical[136] - Other current assets increased by 38.74% compared to the beginning of the period, mainly due to increased unverified input tax, prepaid corporate income tax, and reduced VAT credit balance[136] - Other non-current financial assets increased by 34.58% compared to the beginning of the period, primarily due to a RMB 48.9544 million investment in Japan Hemotech Co., Ltd. and a write-down of investment in Kahtnu Surgical Inc. to zero[136] - Employee compensation payable increased by 56.58% compared to the beginning of the period, mainly due to unpaid wages and bonuses at the end of the reporting period[136] - Taxes payable decreased by 56.95% compared to the beginning of the period, mainly due to a reduction in unpaid VAT and corporate income tax[136] - Deferred income decreased by 32.92% compared to the beginning of the period, mainly due to the completion and transfer of some government subsidy projects to other income accounts[136] - Treasury stock decreased by 99.56% compared to the beginning of the period, mainly due to the failure to meet the unlocking conditions of the third phase of restricted stock and subsequent repurchase and cancellation[137] - Other comprehensive income increased by 148.47% compared to the beginning of the period, mainly due to foreign currency translation differences[137] - Overseas assets accounted for 8.87% of the company's net assets, with Elliquence, LLC generating a net profit of RMB 32.3849 million[137] - The fair value of other non-current financial assets decreased by RMB 18.01982 million during the reporting period[140] - Restricted assets as of the reporting period: Cash and cash equivalents of 4,003,008.83 yuan due to pledged loan guarantees, long-term equity investments of 410,550,965.39 yuan, investment properties of 26,932,208.68 yuan, fixed assets of 127,860,357.13 yuan, and intangible assets of 9,652,573.98 yuan[141] - Total investment in the reporting period increased by 46.18% to 75,214,398.41 yuan compared to the same period last year[144] - Aidi reported revenue of 80.98 million yuan and a net loss of 3.68 million yuan for the reporting period[150] - Elliquence, LLC reported revenue of 168.58 million yuan and net profit of 32.38 million yuan for the reporting period[150] - Jienuo Medical Management Group reported revenue of 192.03 million yuan and net profit of 5.33 million yuan for the reporting period[150] - Elliquence, LLC achieved revenue of 168.58 million RMB and net profit of 32.38 million RMB in the reporting period[159] - Jienuo Medical achieved revenue of 192.03 million RMB and net profit of 5.33 million RMB in the reporting period[161] Centralized Procurement Impact - The company's orthopedic spine, radiofrequency ablation, and trauma products were affected by centralized procurement policies, leading to a significant drop in prices[6] - The company's products were selected in centralized procurement, but the reduced prices negatively impacted the existing distribution system and profit model[6] - In 2021, the average price reduction for orthopedic trauma medical consumables in a 12-province joint procurement was 88.65%, significantly impacting the industry[40] - The company's subsidiary, Aideal, ranked high in clinical demand and bid prices for ordinary bone plate systems and intramedullary nail systems in the procurement[41] - The company faced significant challenges due to the expansion and implementation of centralized procurement policies for high-value medical consumables[92] - The company and its subsidiaries participated in the national orthopedic spine consumables centralized procurement, but the actual procurement volume for 2022 was 0 due to the procurement not being executed[71] - The company anticipates increased competition in the domestic orthopedic market, particularly in the vertebral augmentation minimally invasive surgery segment[181] - The company faces risks from orthopedic centralized procurement policies, which may lead to significant price reductions and potential impacts on profitability[178] Product Portfolio and Innovation - The company's main business is in the production, R&D, sales, and services of orthopedic implant medical devices, including spine minimally invasive products and orthopedic trauma implant devices[37] - The company's product line has expanded from a single spine product to a comprehensive range of orthopedic high-value consumables, including trauma, spine, and minimally invasive joint products, with a focus on developing minimally invasive orthopedic products under the Kelii and Aidier brands[45] - The company's core product, the vertebral augmentation minimally invasive surgery system, has achieved stable growth, with sales expanding from tertiary hospitals to local hospitals, opening up a broader market space[53] - The company completed the acquisition of Elliquence, LLC, which specializes in high-frequency low-temperature, anatomical (monopolar), and coagulation (monopolar and bipolar) technologies, enhancing its presence in the orthopedic equipment sector[49] - The company established a joint venture with Italian company TECRES S.P.A. to develop and produce bone cement products, including spine bone cement, high-viscosity bone cement, antibacterial bone cement, and joint bone cement, enriching its product line[53] - The company acquired 56% of Jienuo Medical to enhance its market competitiveness and profitability through medical sterilization services, which help hospitals reduce operating costs and improve resource allocation efficiency[51] - The company strengthened its distribution network by establishing a joint venture with Sinopharm Holding Medical Devices Co., Ltd., leveraging Sinopharm's brand and financial advantages to expand its market share in medical device sales[50] - The company's subsidiary, Aidier, focuses on the development, production, and sales of orthopedic implants and surgical instruments, with products widely used in trauma and spine surgeries[47] - The company's acquisition of Elliquence, LLC has facilitated the integration of its existing orthopedic resources, enabling the rapid advancement of Elliquence's products in the domestic market[53] - The company has built a comprehensive marketing system in the spinal minimally invasive field, including team building, commercial channel construction, and academic system development, with a professional and market-oriented sales team[54] - The company's joint venture with TECRES S.P.A. has introduced advanced bone cement products and technologies, strengthening its strategic layout and technical accumulation in the medical device field[46] - The company has extensive experience in product promotion, particularly in the vertebral augmentation market, which has established its leading position and accumulated significant expert resources and distribution channels[55] - The company has strengthened its competitive advantage by continuously introducing high-level talent in R&D, quality, and market sales since its IPO in June 2012[56] - The company maintains a strict and standardized quality control system, emphasizing quality as its core value and implementing rigorous supervision across all operational stages[57] - The company has a comprehensive product portfolio covering orthopedic trauma, spine, minimally invasive orthopedic, and radiofrequency ablation, with plans to expand into more innovative minimally invasive products[59] - The company has 4 domestic medical device registration certificates under application, including the Vertebral Lamina Fixation Plate System and Metal Bone Pin[61] - The company has 49 overseas medical device registration applications pending as of December 31, 2022, including products like the KMC Kyphoplasty System and Balloon Catheter, primarily for spinal and orthopedic procedures[62] - The Surgi-Max Ultra series, a new generation of high-frequency hosts for surgical procedures, has been submitted for registration in Egypt, Nicaragua, and Ukraine[63] - The KMC Kyphoplasty System, designed for minimally invasive spinal surgeries, is under review in Pakistan for treating osteoporotic vertebral compression fractures[62] - The Balloon Catheter and Bone Filler Device, both for spinal surgeries, are under review in Turkey[62] - The Surgi-Max Ultra series is classified as IIb and III, targeting advanced surgical applications in orthopedics, arthroscopy, and neurosurgery[63] - The company is expanding its product portfolio with devices like the Vertebral Osteotome and Suture Anchors, currently under review in Turkey and Iran respectively[62] - The Titanium Mesh System and Integrated External Fixation devices are under review in Thailand for cranial and orthopedic applications[63] - The Anatomic Metal Locking Plate & Screw System and Anterior Spinal Plate & Screw System are under review in Thailand for orthopedic and spinal fixation[63] - The Centrum Fusion Device, designed for spinal fusion surgeries, is under review in Thailand[63] - The company is focusing on international market expansion with registration applications in multiple countries including Pakistan, Turkey, Iran, Thailand, Egypt, Nicaragua, and Ukraine[62][63] - Surgi-Max® Ultra series, a new generation of high-frequency hosts, has been submitted for approval in multiple countries including the Dominican Republic, Belarus, and the Philippines[64][30][31] - Trigger-Flex® bipolar system, designed for soft tissue coagulation/shrinkage, has been submitted for approval in countries such as Nicaragua, Egypt, and the Philippines[32][33][34] - Disc-FX family system, used for ablation and coagulation of intervertebral disc material, has been submitted for approval in countries including the Dominican Republic, Nicaragua, and Belarus[37][38][39] - Endiscope, suitable for visualization during spinal endoscopy and minimally invasive surgeries, has been submitted for approval in countries such as Egypt, Japan, and the Dominican Republic[42][43][44] - Elliquence's imported products (endoscopic surgical instruments, spinal endoscopes, high-frequency surgical equipment, nucleus forceps) have completed registration and are expected to fill the gap in the company's spinal endoscopy product line[122] - The expandable interbody fusion device and supporting instruments are in the product design phase, aiming to enhance the company's spine product offerings[122] - The lamina fixation plate system is under registration review, which will benefit the company's spine product series[122] - The company has obtained a Class III medical device registration certificate for spinal bone cement through its joint venture with TECRES S.P.A and will accelerate the registration of other bone cement products[176] Subsidiaries and Acquisitions - The company's subsidiary, Jiangsu Aidier Medical Technology Co., Ltd., won bids for various orthopedic trauma products in the 8th round of volume-based procurement in Jiangsu Province, with prices ranging from 1,716 RMB to 2,450 RMB per product[78][79

证券代码：300326 证券简称：凯利泰 上海凯利泰医疗科技股份有限公司 投资者关系活动记录表 编号：2015-02 | --- | --- | --- | |-----------------------------|------------------------------|-----------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 中信证券 研究部研究员 田加强 | | | 人员姓名 | 中信证券 研究部研究员 许拓 | | | 时间 | 2015 年 7 月 24 | 日 | | 地点 | | 上海凯利泰医疗科技股份有限公司 4 楼 | | 上市公司接待人 | 董事会秘书 丁魁 | | | 员姓名 | | | | | | | | 投资者关系活动 主要内容介绍 | 详见附件 | | | 附 件 ...

证券代码：300326 证券简称：凯利泰 上海凯利泰医疗科技股份有限公司 投资者关系活动记录表 编号：2015-01 | --- | --- | --- | |-------------------|--------------------------------|----------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 中国国际金融有限公司 研究部研究员 邹朋 | | 人员姓名 | | 中国国际金融有限公司 研究部研究员 代雯 | | 时间 | 2015 年 3 月 20 日 | | | 地点 | 上海凯利泰医疗科技股份有限公司 | 4 楼 | | 上市公司接待人 | 董事会秘书 丁魁 | | | 员姓名 | | | | 投资者关系活动 | | | | 主要内容介绍 | 详见会议记录 | | | ...

证券代码：300326 证券简称：凯利泰 上海凯利泰医疗科技股份有限公司 投资者关系活动记录表 编号：2016-05 | --- | --- | --- | --- | |-------------------|-------------------------------------------------|----------------------------------------------------|--------------------| | | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | | 类别 | □ | 媒体采访 □业绩说明会 | | | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | □ | 其他 （请文字说明其他活动内容） | | | 参与单位名称及 | | 广发证券 发展研究中心 医药行业分析师 马帅 | | | | | | | | 人员姓名 | 汇添富基金 研究员 付鹏飞 招商基金 研究员 周雨婷 | | | | 时间 | 2016 年 7 月 4 | 日 | | | 地点 | | 上海凯利泰医疗科技股份 ...